Full Year 2025 Dr Reddy's Laboratories Ltd Earnings Call Transcript

May 9, 2025 / 02:00 PM GMT

Release Date Price: €12 (+2.56%)

Transcript

Key Points

Positve

Dr Reddy's Laboratories Ltd (RDY) achieved record high revenue exceeding $3.8 billion and crossed the $1 billion threshold in EBITDA for the first time.
The company reported a year-over-year revenue growth of 17% for the full year, driven by strategic acquisitions and contributions from its generic portfolio.
EBITDA margins remained resilient, exceeding 29% for the quarter and closing the full year at over 28%.
The company successfully integrated its newly acquired nicotine replacement therapy business in the UK and is on track to complete integration in the Nordics.
Dr Reddy's Laboratories Ltd (RDY) maintained a net cash surplus balance of 2,454 crores post-acquisition payouts, enhancing financial flexibility for future growth initiatives.

Negative

The consolidated gross profit margin for the fourth quarter declined by 300 basis points year-over-year, primarily due to reduced manufacturing overhead leverage.
Selling and general administrative expenses increased by 22% year-over-year, driven by the acquired consumer healthcare business and higher logistics costs.
The effective tax rate for the full year was higher than the previous year, mainly due to the reversal of previously recognized deferred tax assets.
The company faced impairment losses of 77 crores in Q4 and 169 crores for the full year, related to certain product-related intangibles due to adverse market conditions.
There was a sequential decline of 30% in the emerging markets generic business revenue for Q4, despite a year-over-year growth of 16%.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

REDY.NS - Dr Reddy's Laboratories Ltd
Full Year 2025 Dr Reddy's Laboratories Ltd Earnings Call
May 09, 2025 / 02:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, good evening and welcome to quarter fo and full year FI 25 earnings conference call of Doctor Reddy's Laboratories Limited.

As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes.

Should you need assistance during this conference call, please signal an operator by pressing, then 0 on your touchtone phone.

And I'll hand the conference. Oman Riha Perivar.

Thank you and over to you, ma'am.

--------------------------------------------------------------------------------
Unidentified_2 [2]
-----------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.